{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:35:24Z","timestamp":1761885324002,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.acuroe.2022.01.002","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T18:13:39Z","timestamp":1646763219000},"page":"329-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Active surveillance protocol in prostate cancer in Portugal"],"prefix":"10.1016","volume":"46","author":[{"given":"S.R.","family":"Silva Gaspar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Santos Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Palma dos Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2022.01.002_bib0005","first-page":"1","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00345-019-02662-5","article-title":"Evidence-based approach to active surveillance of prostate cancer","volume":"38","author":"Witherspoon","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0015","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/pcan.2016.30","article-title":"Increasing incidence of metastatic prostate cancer in the United States (2004-2013)","volume":"19","author":"Weiner","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM199401273300403","article-title":"Results of conservative management of clinically localized prostate cancer","volume":"330","author":"Chodak","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0025","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrurol.2017.26","article-title":"Expert consensus document: semantics in active surveillance for men with localized prostate cancer \u2014 results of a modified Delphi consensus procedure","volume":"14","author":"Bruinsma","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0030","doi-asserted-by":"crossref","first-page":"256","DOI":"10.21037\/tau.2018.01.12","article-title":"The future of active surveillance","volume":"7","author":"Klotz","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0035","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0022-5347(05)65174-9","article-title":"Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and\/or clinical progression","volume":"167","author":"Choo","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0040","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2016.10.031","article-title":"Quantifying the transition from active surveillance to watchful waiting among men with very low-risk prostate cancer","volume":"72","author":"Hemelrijck","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0045","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11934-004-0033-7","article-title":"Patterns of practice in the United States: insights from CaPSURE on prostate cancer management","volume":"5","author":"Cooperberg","year":"2004","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0050","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.eururo.2012.05.072","article-title":"Active surveillance for prostate cancer: a systematic review of the literature","volume":"62","author":"Dall\u2019Era","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0055","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/jso.23584","article-title":"Active surveillance for clinically localized prostate cancer \u2014 a systematic review","volume":"109","author":"Thompsen","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0060","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.urology.2018.06.037","article-title":"National trends in active surveillance for prostate cancer: validation of medicare claims-based algorithms","volume":"120","author":"Modi","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0065","series-title":"Trends in Initial Management of Prostate Cancer in New Hampshire","first-page":"777","author":"Ingimarsson","year":"2015"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.juro.2014.07.111","article-title":"National trends in the management of low and intermediate risk prostate cancer in the United States","volume":"193","author":"Weiner","year":"2015","journal-title":"J Urol"},{"year":"2017","series-title":"Clinically localized prostate cancer, AUA\/ASTRO\/SUO GUIDELINE","author":"Sanda","key":"10.1016\/j.acuroe.2022.01.002_bib0075"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0080","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JOP.18.00434","article-title":"Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an AUA\/ASTRO\/SUO guideline summary","volume":"14","author":"Bekelman","year":"2018","journal-title":"J Oncol Pract"},{"year":"2020","series-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer 2020","author":"Mottet","key":"10.1016\/j.acuroe.2022.01.002_bib0085"},{"author":"National Comprehensive Cancer Network","key":"10.1016\/j.acuroe.2022.01.002_bib0090"},{"author":"National Institute for Health and Care Excellence","key":"10.1016\/j.acuroe.2022.01.002_bib0095"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clgc.2017.10.021","article-title":"Active surveillance for low and intermediate risk prostate cancer: opinions of North American genitourinary oncology expert radiation oncologists","volume":"16","author":"McClelland","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0105","first-page":"e33","article-title":"Predicting insignificant prostate cancer: analysis of the pathological outcomes of candidates for active surveillance according to the pre-international society of urological pathology (Pre-ISUP) 2014 era versus the post-ISUP2014 era","volume":"38","author":"Chung","year":"2020","journal-title":"World J Mens Health"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0110","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.29874","article-title":"Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies","volume":"122","author":"Filson","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0115","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.eururo.2018.06.008","article-title":"Active surveillance for low-risk prostate cancer: the European association of urology position in 2018","volume":"74","author":"Briganti","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0120","doi-asserted-by":"crossref","DOI":"10.1177\/1756287220916613","article-title":"The role of MRI\/TRUS fusion biopsy in the diagnosis of clinically significant prostate cancer","volume":"12","author":"Benelli","year":"2020","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0125","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.juro.2018.09.054","article-title":"Three tesla multiparametric magnetic resonance imaging: comparison of performance with and without endorectal coil for prostate cancer detection, PI-RADSTM version 2 category and staging with whole mount histopathology correlation","volume":"201","author":"Mirak","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0130","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0135","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.eururo.2020.03.035","article-title":"Five-year outcomes of magnetic resonance imaging-based active surveillance for prostate cancer: a large cohort study","volume":"78","author":"Stavrinides","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0140","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.juro.2016.04.057","article-title":"Prospective evaluation of the prostate imaging reporting and data system version 2 for prostate cancer detection","volume":"196","author":"Mertan","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0145","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1148\/radiol.2017152877","article-title":"What are we missing? False-negative cancers at multiparametric MR imaging of the prostate","volume":"286","author":"Borofsky","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0150","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s00330-013-2795-0","article-title":"Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study","volume":"23","author":"Bratan","year":"2013","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.acuroe.2022.01.002_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/pcan.2016.51","article-title":"Active surveillance for intermediate risk prostate cancer","volume":"20","author":"Dall\u2019Era","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2020.05.008","article-title":"Active surveillance for intermediate-risk prostate cancer: systematic review and meta-analysis of current protocols and outcomes","author":"Enikeev","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.acuroe.2022.01.002_bib0185","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.euo.2020.09.002","article-title":"Can the use of serial multiparametric magnetic resonance imaging during active surveillance of prostate cancer avoid the need for prostate biopsies? A systematic diagnostic test accuracy review","volume":"4","author":"Hettiarachchi","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.21037\/tau.2017.12.26","article-title":"Biomarkers in active surveillace","author":"Loeb","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0195","article-title":"Incorporating MRI and biomarkers in active surveillance protocols \u2014 results from the prospective Stockholm3 Active Surveillance trial (STHLM3AS)","author":"Olsson","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0200","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.juro.2013.08.088","article-title":"The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance","volume":"191","author":"Vertosick","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0205","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bju.13410","article-title":"Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: active surveillance (PRIAS) study","volume":"118","author":"Bokhorst","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.acuroe.2022.01.002_bib0210","first-page":"645","article-title":"How do prostate cancer patients navigate the active surveillance journey? A 3-year longitudinal study","volume":"29","author":"Dordoni","year":"2020","journal-title":"Support Care Cancer"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578622000026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578622000026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:14:50Z","timestamp":1761880490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578622000026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2173578622000026"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2022.01.002","relation":{},"ISSN":["2173-5786"],"issn-type":[{"type":"print","value":"2173-5786"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Active surveillance protocol in prostate cancer in Portugal","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2022.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2021.01.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of AEU.","name":"copyright","label":"Copyright"}]}}